You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

20 Results
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Palliative, Curative
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Advanced or Recurrent Endometrial Cancer
Oct 2024
Guidelines and Advice
Drug
Other Name(s): Trecondyv®
Jan 2025
Drug
Other Name(s): Tukysa™
Feb 2025
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Feb 2025
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Palliative
May 2025
Drug
Other Name(s): Mekinist®
Jun 2025
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
    trametinib - As monotherapy in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, according to specific criteria
Jun 2025
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Jul 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Teclistamab (Outpatient) - Relapsed or Refractory Multiple Myeloma
High Cost Therapy Funding Program
    Teclistamab (Inpatient) - Relapsed or Refractory Multiple Myeloma
Jul 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Jul 2025

Pages